Sonnet BioTherapeutics Holdings, Inc. (SONN) Cash flow
Market cap
$1.26
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Depreciation & amortization | 87,617 | 383,454 | 622,274 | 2 | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - | - | - | 126,829 | 876,368 | 248,626 | 231,190 | 199,595 |
| Cash from operations | -1,044,407 | -2,353,910 | -2,704,199 | -1,003,745 | -5,363,324 | -434,158 | -724,432 | 575,218 | -4,046,550 | -27,687,278 | -21,341,842 | -8,607,723 | -12,827,199 |
| Capital expenditures | -388,109 | -1,173,801 | -3,658,224 | -1,970,173 | -1,798,221 | -1,191,174 | -1,625,460 | -2,392,864 | -472,882 | - | - | - | - |
| Cash from investing | -1,653,744 | -2,616,421 | -4,065,205 | -2,171,424 | -10,490,651 | -1,254,487 | -1,164,302 | -2,442,864 | 678,669 | -896,477 | -443,250 | -12,000 | -12,000 |
| Repurchases of common stock | -500 | - | - | - | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | 3 | 3 | 4 | 2 | 663,074 | 275,000 | 7 | 100,000 | - | - | - | - | - |
| Cash from financing | 3 | 6 | 6 | 3 | 17 | 801,687 | 2 | 2 | 3 | 4 | 21 | 6 | 26 |
| Free cash flow | - | - | - | - | |||||||||
| FCF margin (%) | - | - | - | - |